Latest Biotech News

Cellares secured a long‑term lease in Leiden Bio Science Park to establish a Smart Factory and serve as its European integrated development and manufacturing organization (IDMO) headquarters. The...

Researchers introduced CLASSIC, a method combining long‑ and short‑read sequencing with AI/ML to design, build and map hundreds of thousands to millions of genetic circuit variants in human cells,...

Johnson & Johnson reported Phase 3 results showing Tecvayli (a dual‑targeting T‑cell engager) produced a large survival and progression benefit in relapsed multiple myeloma. In the MajesTEC‑9...

Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion, a cash‑and‑stock deal that gives the acquirer expanded thrombectomy and embolization capabilities. Penumbra makes...

Agenus finalized a $141 million strategic collaboration with Zydus Lifesciences to accelerate global development and commercial readiness for its BOT+BAL immunotherapy combination. The agreement...

Cellares signed a long‑term lease for a Smart Factory at Leiden Bio Science Park to serve as its European headquarters and expand automated cell‑therapy development and manufacturing capacity. The...

Two major partnerships announced at JPM highlight an acceleration of AI investments across drug discovery and laboratory workflows. NVIDIA and Eli Lilly unveiled a $1 billion co‑innovation lab to...

Veracyte outlined plans to launch its TrueMRD minimal residual disease test in the first half of the year with an initial indication in muscle‑invasive bladder cancer and a pipeline across breast,...

Researchers published PanMAN (Pangenome Mutation‑Annotated Network), a data structure and compression approach in Nature Genetics designed to dramatically reduce storage and compute burdens for...

Mass General Brigham researchers reported a disease‑severity‑responsive nanoparticle platform (MINT) that preferentially delivers ghrelin mRNA to cartilage regions undergoing glycosaminoglycan...

Ocugen reported interim Phase 2 data for its geographic atrophy gene therapy program showing positive signals from a limited patient cohort. Company statements said the candidate demonstrated...

Oxford Biomedica, a major contract manufacturer for cell and gene therapies, confirmed takeover talks with private equity investor EQT after rejecting multiple bids it deemed to undervalue the...

BloodPAC published standardized analytical-validation protocols for tumor‑informed circulating tumor DNA (ctDNA) assays, setting a common blueprint for how companies should demonstrate limit of...

Johnson & Johnson reported Phase 3 results showing Tecvayli reduced risk of disease progression or death versus standard regimens in patients who relapsed after frontline therapy, with the company...

NVIDIA and Eli Lilly announced a five‑year, $1 billion co‑innovation lab to deploy large‑scale AI computing and models for drug discovery, signaling a major industry pivot to tightly integrated...

Boston Scientific agreed to acquire Penumbra for about $14.5 billion in cash and stock, a deal that would add Penumbra’s thrombectomy and embolization platforms to Boston Scientific’s...

Oxford Biomedica, a major contract‑manufacturer for cell and gene therapy, confirmed it has engaged in takeover talks with private equity investor EQT after turning down prior unsolicited bids the...

Cellares signed a long‑term lease at Leiden Bio Science Park for a new Integrated Development and Manufacturing Organization (IDMO) Smart Factory that will serve as the company’s European...

The Novo Nordisk Foundation pledged up to DKK 5.5 billion (about €736 million / ~$857 million) to the BioInnovation Institute (BII) to expand operations, increase the number of startups supported...

Caldera Therapeutics emerged from stealth with $112.5 million in combined Series A and A‑1 financing to advance CLD‑423, a dual‑targeting bispecific licensed from China’s Qyuns Therapeutics for...